Eli Lilly has entered into a strategic partnership with Hong Kong-based Metis TechBio valued at up to $1.1 billion. Under the agreement, Lilly gains access to Metis’ proprietary AiLNP platform, an artificial intelligence algorithm designed to discover and optimize ionizable lipids. The collaboration aims to improve targeted drug delivery, tissue penetration, and the stability of lipid nanoparticles used in advanced genetic and RNA therapeutics. Metis will receive an upfront payment in the low double-digit millions, along with potential development milestones and commercial royalties. The agreement underscores Lilly’s broader strategy of combining artificial intelligence with specialized delivery technologies to accelerate drug development.

Full report : Eli Lilly teams up with Metis’ AI-driven platform to optimize lipid nanoparticle delivery systems for next-generation therapeutics.